Brian Achenbach Biography and Net Worth

SVP of Mustang Bio

Mr. Achenbach has served as Senior Vice President of Finance & Corporate Controller since March 2019 after joining Mustang Bio in October 2017 as Vice President of Finance & Corporate Controller. Prior to Mustang, Mr. Achenbach served as Vice President & Corporate Controller at Amerigen Pharmaceuticals, where he oversaw finance and accounting functions as the company established itself as a commercial organization in the U.S. and China. Prior to Amerigen, Mr. Achenbach served as Vice President of Finance for the Americas and Vice President of Global Financial Planning & Analysis at ConvaTec, a global medical products and technologies company, where he led finance and accounting operations in the U.S., Canada and South America. Earlier in his career, Mr. Achenbach held roles of increasing responsibility in finance and accounting at Mylan, Andrx (acquired by Watson Pharmaceuticals) and IVAX (acquired by Teva Pharmaceuticals). Mr. Achenbach holds an M.B.A. in finance from Roosevelt University in Chicago and a B.A. in economics from the University of Florida in Gainesville.

How do I contact Brian Achenbach?: The corporate mailing address for Mr. Achenbach and other Mustang Bio executives is 377 PLANTATION STREET, WORCESTER MA, 01605. Mustang Bio can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on Brian Achenbach's contact information.
Has Brian Achenbach been buying or selling shares of Mustang Bio?: Brian Achenbach has not been actively trading shares of Mustang Bio in the last ninety days. Most recently, Brian Achenbach sold 291 shares of the business's stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $27.45, for a transaction totalling $7,987.95. Learn More on Brian Achenbach's trading history.
Who are Mustang Bio's active insiders?: Mustang Bio's insider roster includes Brian Achenbach (SVP), and Manuel Litchman (CEO). Learn More on Mustang Bio's active insiders.

Brian Achenbach Insider Trading History at Mustang Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/14/2021	Sell	291	$27.45	$7,987.95
10/12/2021	Sell	296	$34.20	$10,123.20
4/9/2021	Sell	161	$50.40	$8,114.40
3/31/2021	Sell	202	$39.60	$7,999.20

Brian Achenbach Buying and Selling Activity at Mustang Bio

Mustang Bio Company Overview

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Today's Range

Now: $0.27

$0.26

$0.29

50 Day Range

MA: $0.26

$0.21

$0.35

2 Week Range

Now: $0.27

$0.13

$1.97

Volume

702,598 shs

Average Volume

9,478,626 shs

Market Capitalization

$9.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.